Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 9128 results

  1. Social work interventions for adults with complex needs (including learning disabilities) and mental health needs

    Awaiting development Reference number: GID-QS10148 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]

    Awaiting development Reference number: GID-TA10885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development Reference number: GID-QS10097 Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Safeguarding adults in care homes

    Awaiting development Reference number: GID-QS10147 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development Reference number: GID-QS10149 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Pridopidine for treating Huntington's disease [ID6525]

    Awaiting development Reference number: GID-TA11637 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  11. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 9 July 2026.

    Technology appraisal guidance
    In consultation

  12. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  13. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy ID6711: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 13 August 2026.

    Technology appraisal guidance
    In consultation

  14. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6625: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 13 August 2026.

    Technology appraisal guidance
    In consultation

  15. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    Awaiting development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    Awaiting development